BLINCYTO

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, Turkey, United Kingdom, South Africa

Active ingredients

The drug BLINCYTO contains one active pharmaceutical ingredient (API):

1 Blinatumomab UNII 4FR53SIF3A - BLINATUMOMAB

Blinatumomab is a bispecific T-cell engager molecule that binds specifically to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T-cells. It activates endogenous T-cells by connecting CD3 in the T-cell receptor (TCR) complex with CD19 on benign and malignant B-cells. The anti-tumour activity of blinatumomab immunotherapy is not dependent on T-cells bearing a specific TCR or on peptide antigens presented by cancer cells, but is polyclonal in nature and independent of human leukocyte antigen (HLA) molecules on target cells. Blinatumomab mediates the formation of a cytolytic synapse between the T-cell and the tumour cell, releasing proteolytic enzymes to kill both proliferating and resting target cells. Read about Blinatumomab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
BLINCYTO Powder and solution for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FX07	Blinatumomab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 11115B, 11116C, 11117D, 11118E, 11119F, 11120G, 11799B, 11814T, 11850Q, 11867N
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 544117080004101
Country: CA	Health Products and Food Branch	Identifier(s): 02450283
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 169-MBE-1120
Country: EE	Ravimiamet	Identifier(s): 1706048
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 462169
Country: FR	Base de données publique des médicaments	Identifier(s): 62003633
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 311441
Country: HK	Department of Health Drug Office	Identifier(s): 65074
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 7802
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291445D1029
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1078868
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 129704
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100358980
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W62507001
Country: SG	Health Sciences Authority	Identifier(s): 15103P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699862270021
Country: ZA	Health Products Regulatory Authority	Identifier(s): 54/26/0736